PETROCHINA
00857
ABC
01288
CHINA SHENHUA
01088
BANKCOMM
03328
KB LAMINATES
01888
HK Stock MarketDetailed Quotes
02509 QYUNS-B
- 7.000
- +0.010+0.14%
Market Closed Jan 3 16:08 CST
1.55BMarket Cap-3.36P/E (TTM)
7.000High6.980Low7.60KVolume6.980Open6.990Pre Close53.11KTurnover0.00%Turnover RatioLossP/E (Static)222.07MShares30.95052wk High3.86P/B1.43BFloat Cap6.98052wk Low--Dividend TTM204.75MShs Float30.950Historical High--Dividend LFY0.29%Amplitude6.980Historical Low6.987Avg Price200Lot Size--Div YieldTTM--Div Yield LFY
QYUNS-B News
CICC: Maintains HANSOH PHARMA "Outperform Industry" rating with a Target Price of HKD 21.12.
CICC released a research report stating that it maintains a "outperform the Industry" rating for HANSOH PHARMA (03692), being Bullish on the company's future progress in going global, and maintains a Target Price of HKD 21.12. Due to the possibility that the initial payment for this authorized cooperation may be confirmed in 2025, the bank has lowered its expectations for 2024 authorized revenue and maintained its expectations for 2025 authorized fees, thus reducing the 2024 profit forecast by 9.7% to 4.04 billion yuan while keeping the 2025 profit forecast unchanged. On December 18, 2024, the company announced the granting of a global exclusive license agreement for Merck's HS-10535 (oral GLP-1 receptor agonist). CICC
Annual Review | The 2024 Hong Kong IPO rankings have been released! Mao Ge Ping and Lao Pu Gold surged over 70% on debut! Jingwei Tiandi made a spectacular profit of 6,560 HKD.
Hong Kong, as one of the important Global international financial centers, has been the largest Global IPO financing center seven times since 2009.
Chuanxin Biotechnology-B (02509.HK): Non-executive Director Xue Mingyu has resigned.
On December 10, Glonhui reported that the non-executive director Xue Mingyu has submitted his resignation from his position as a non-executive director and member of the global strategy development committee due to personal matters requiring more time, effective from December 10, 2024. Xue Mingyu will serve as a consultant to the company.
Kunxin Biotech-B(02509.HK): Supplemental application for QX001S (Ustekinumab Injection) for children with plaque psoriasis has been accepted.
On December 2nd, Glorious Exchange announced that Quanxin Biotechnology-B (02509.HK) has made public announcements regarding the framework agreement QX001S signed with Hangzhou ZMC East China Pharmaceutical Co., Ltd. ("ZMC East China"), with the publication date of September 12, 2024, containing information about the supplementary agreement of the "Ushikuzuma Monoclonal Antibody Contract Manufacturing Agreement" signed between ZMC East China and the company's subsidiary Jiangsu Safus Biotechnology Co., Ltd. ("Safus"), as well as the annual limit for the QX001S framework agreement. Additionally, an announcement was made on November 5, 2024, regarding ZMC East China receiving national pharmaceutical approvals.
Hong Kong stock movement | Qianxin Biotech-B (02509) rises over 7% as the application for the marketing authorization of ustekinumab injection has been approved.
Hysan Bio-B (02509) increased by over 7%, as of the time of writing, it rose by 7.69%, trading at 14 Hong Kong dollars, with a transaction amount of 0.451 million Hong Kong dollars.
Sorrento Therapeutics-B (02509): QX001S (Selexin, Ustekinumab Injection) obtained the pharmaceutical registration certificate approved and issued by the National Medical Products Administration
Chun Shin Biologics -B (02509) issued an announcement. On November 5, 2024, Sino-American East received the National Pharmaceutical Administration...
Announcement Selection | CNOOC's net income in the first three quarters exceeded 116.6 billion yuan, a year-on-year increase of 19.5%; wuxi apptec orders in hand increased by more than 30% year-on-year.
①CNOOC's net income exceeded 110 billion yuan in the first 9 months, how fast is the growth? ②How is the profit performance of WuXi AppTec's year-on-year growth in hand orders?
China San Bio-B (02509.hong kong): China Securities Regulatory Commission accepts the company's H股 full circulation plan application.
Great Wisdom October 28th | Transtech Bio-B (02509.HK) announced that the China Securities Regulatory Commission has recently accepted the company's shareholders' suggestions to implement the application for full circulation of H shares. According to the relevant application documents, the company has applied to convert the 17,322,400 shares held by these shareholders of the company into H shares and list them on the HKEX, accounting for approximately 7.80% of the company's total issued share capital as of the announcement date. After the full circulation of H shares, all domestic shareholders participating in the full circulation of H shares will still need to comply with the stock lock-up requirements stipulated by the HKEX securities listing rules and applicable laws and regulations.
Hopson Development Holdings Limited-B (02509): Wang Yujiao re-elected as employee representative supervisor.
BBIG Pharmaceutical-B (02509) announced that the company will hold a staff representative congress on October 24, 2024, ...
Third quarter IPO report: Hong Kong stock market once again witnessed billion-dollar projects, the number and amount of Chinese enterprise IPOs rebounded year-on-year
In Q3 2024, a total of 52 Chinese companies successfully IPO'd on A-shares, Hong Kong stocks, and US stocks. The number of IPOs decreased by 52.29% year-on-year, but increased by 18.18% compared to the previous period. In the first three quarters, the number of IPOs of Chinese companies globally decreased by 54.98% year-on-year.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
Hong Kong stocks are on the move | Namchong Bio-B (02509) rose more than 7%. Achieved revenue of 44.919 million yuan in the first half of the year. Previously collaborated with huadong medicine.
Tshing Shing Biological - B (02509) rose more than 7%, as of the time of publication, it increased by 7.54% to 24.95 Hong Kong dollars.
QYUNS-B: 2024 INTERIM REPORT
Qyuns Therapeutics Shrinks Loss in H1
Performance: Quanxin Biotech (02509.HK) narrowed its half-year loss to 0.172 billion RMB.
China Medical System Holdings Ltd. - B (02509.HK) announced its interim results for the six months ended in June, with revenue reaching 449.2 million yuan (same below). The loss narrowed from 0.258 billion yuan in the same period last year to 0.172 billion yuan, with a loss per share of 79 cents. No interim dividend will be paid.
China Create Bio-B (02509) released its interim results, achieving revenue of 44.919 million yuan.
Quanxin Biopharmaceutical-B (02509) released the unaudited interim results for the six months ending June 30, 2024,...
Qunxing Biologics-B (02509.HK) announced its interim performance. It continues to optimize the CMC quality management system and improve production efficiency, seeking opportunities for overseas expansion.
On August 15th, Grontmij released an announcement. For a six-month period ending on June 30, 2024, the group's revenue was 449.2 million yuan, which was generated from royalty income and research and development service fees from QX008N and QX004N authorized transactions, reflecting the group's strong research and development capabilities. As of July 31, 2024, the company holds 43 patents in China, including 34 invention patents and 9 utility model patents, and 9 patents overseas. As of the same date, the company also has 46 patent applications in China and overseas awaiting approval.
QYUNS-B: UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Quanxin Biology-B (02509.HK) will hold a board of directors' meeting on August 15 to approve its interim performance.
On August 5th, Guolong Announcement, Bio-B (02509.HK) announced that the company's board of directors meeting will be held on August 15, 2024 to consider and approve the group's six-month interim performance ending on June 30, 2024 and its release, as well as handling other matters.
QYUNS-B: NOTICE OF BOARD MEETING
Trending HK Stocks
HK Dividend Stocks HK Dividend Stocks
Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.
